The m7Gscore can be applied as an independent marker for the BCR-free survival of PCa patients and also provide effective guidance for clinicians to formulate chemotherapy, endocrine therapy, and immunotherapy strategies. The gene discussed is BCR; the disease is posterior cortical atrophy.